Metalloprotease-mediated GH Receptor Proteolysis and GHBP Shedding
Xiangdong Wang,Kai He,Mary Gerhart,Yao Huang,Jing Jiang,Raymond J. Paxton,Shaohua Yang,Chunxia Lü,Ram K. Menon,Roy A. Black,Gerhard Baumann,Stuart J. Frank
DOI: https://doi.org/10.1074/jbc.m208738200
2002-01-01
Abstract:Growth hormone-binding protein (GHBP) is complexed to a substantial fraction of circulating GH. In humans, rabbits, and other species, GHBP derives from proteolytic shedding of the GH receptor (GHR) extracellular domain. In cell culture studies, stimuli such as phorbol ester, platelet-derived growth factor, or serum induce GHR proteolysis, which concomitantly yields shed GHBP in cell supernatants and a cell-associated cytoplasmic domain-containing GHR remnant. This process is sensitive to metalloprotease inhibition, and genetic reconstitution studies identify tumor necrosis factor-α converting enzyme (TACE/ADAM-17), a transmembrane metalloprotease, as a GHR sheddase. Stimuli that induce GHR proteolysis render cells less responsive to GH, but the mechanism(s) of this desensitization is not yet understood. In this study, we mapped the rabbit (rb) GHR cleavage site. We adenovirally expressed a C-terminal epitope-tagged rbGHR lacking most of its cytoplasmic domain, purified the remnant protein induced by the phorbol ester, PMA, and derived the cleavage site by N-terminal sequencing of the purified remnant. The N-terminal sequence,239FTCEEDFR246, matched perfectly the rbGHR and suggests that cleavage occurs eight residues from the membrane in the proximal extracellular domain stem region. Deletion and alanine substitution mutagenesis indicated that, similar to other TACE substrates, the spacing of residues in this region, more than their identity, influences GHR cleavage susceptibility. Further, we determined that PMA pretreatment desensitized a cleavage-sensitive GHR mutant, but not a cleavage-insensitive mutant, to GH-induced JAK2 activation. These results suggest that inducible GHR proteolysis can regulate GH signaling. Growth hormone-binding protein (GHBP) is complexed to a substantial fraction of circulating GH. In humans, rabbits, and other species, GHBP derives from proteolytic shedding of the GH receptor (GHR) extracellular domain. In cell culture studies, stimuli such as phorbol ester, platelet-derived growth factor, or serum induce GHR proteolysis, which concomitantly yields shed GHBP in cell supernatants and a cell-associated cytoplasmic domain-containing GHR remnant. This process is sensitive to metalloprotease inhibition, and genetic reconstitution studies identify tumor necrosis factor-α converting enzyme (TACE/ADAM-17), a transmembrane metalloprotease, as a GHR sheddase. Stimuli that induce GHR proteolysis render cells less responsive to GH, but the mechanism(s) of this desensitization is not yet understood. In this study, we mapped the rabbit (rb) GHR cleavage site. We adenovirally expressed a C-terminal epitope-tagged rbGHR lacking most of its cytoplasmic domain, purified the remnant protein induced by the phorbol ester, PMA, and derived the cleavage site by N-terminal sequencing of the purified remnant. The N-terminal sequence,239FTCEEDFR246, matched perfectly the rbGHR and suggests that cleavage occurs eight residues from the membrane in the proximal extracellular domain stem region. Deletion and alanine substitution mutagenesis indicated that, similar to other TACE substrates, the spacing of residues in this region, more than their identity, influences GHR cleavage susceptibility. Further, we determined that PMA pretreatment desensitized a cleavage-sensitive GHR mutant, but not a cleavage-insensitive mutant, to GH-induced JAK2 activation. These results suggest that inducible GHR proteolysis can regulate GH signaling. growth hormone GH receptor GH-binding protein endoglycosidase H phosphate-buffered saline phorbol 12-myristate 13-acetate human embryonic kidney green fluorescent protein wild type a disintegrin and metalloprotease tumor necrosis factor-α-converting enzyme Janus-activating kinase dimethyl sulfoxide Growth hormone (GH)1 is an anterior pituitary-derived hormone that exerts somatogenic and metabolic effects by interacting with the GH receptor (GHR) on target cells (1Isaksson O.G.P. Eden S. Jansson J.-O. Annu. Rev. Physiol. 1985; 47: 483-499Crossref PubMed Google Scholar). The GH-bound dimerized GHR causes engagement of intracellular signaling cascades by activating the receptor-associated cytoplasmic tyrosine kinase, JAK2 (2Argetsinger L.S. Campbell G.S. Yang X. Witthuhn B.A. Silvennoinen O. Ihle J.N. Carter-Su C. Cell. 1993; 74: 237-244Abstract Full Text PDF PubMed Scopus (815) Google Scholar). Activation of pathways including the signal transducer and activator of transcription (STAT) 5, MAP kinase, and phosphatidylinositol 3-kinase pathways, results in expression of insulin-like growth factor-1 and other target genes that contribute to GH effects (3Carter-Su C. Schwartz J. Smit L.S. Annu. Rev. Physiol. 1996; 58: 187-207Crossref PubMed Scopus (273) Google Scholar, 4Frank S.J. Messina J.L. Oppenheim J.J. Feldman M. Cytokine Reference On-Line. Academic Press, Harcourt, London, UK2002Google Scholar). A substantial fraction (roughly one-half in humans) of circulating GH is bound to a high-affinity GH-binding protein (GHBP), which corresponds to the extracellular ligand-binding domain of the GHR (5Leung D.W. Spencer S.A. Cachianes G. Hammonds R.G. Collins C. Henzel W.J. Barnard R. Waters M.J. Wood W.I. Nature. 1987; 330: 537-543Crossref PubMed Scopus (1318) Google Scholar,6Baumann G. Amburn K. Shaw M.A. Endocrinology. 1988; 122: 976-984Crossref PubMed Scopus (149) Google Scholar). Depending on species, GHBP is generated by two distinct mechanisms. In rodents, alternative splicing of the GHR mRNA yields a secreted form that includes the extracellular domain (7Baumbach W.R. Horner D.L. Logan J.S. Genes Dev. 1989; 3: 1199-1205Crossref PubMed Scopus (379) Google Scholar, 8Smith W.C. Kuniyoshi J. Talamantes F. Mol. Endocrinol. 1989; 3: 984-990Crossref PubMed Scopus (289) Google Scholar, 9Sadeghi H. Wang B.S. Lumanglas A.L. Logan J.S. Baumbach W.R. Mol. Endocrinol. 1990; 4: 1799-1805Crossref PubMed Scopus (105) Google Scholar). In humans, rabbits, and other species, GHBP is derived by proteolysis of the GHR (reviewed in Ref. 10Baumann G. J. Ped. Endocrinol. Metab. 2001; 14: 355-375Crossref PubMed Scopus (118) Google Scholar). This yields a soluble receptor extracellular domain in a process termed proteolytic GHBP shedding. An obligatory byproduct of proteolytic GHBP shedding is the so-called GHR “remnant”, a cytoplasmic domain-containing cell-associated fragment of the receptor that remains after the extracellular domain is shed (11Alele J. Jiang J. Goldsmith J.F. Yang X. Maheshwari H.G. Black R.A. Baumann G. Frank S.J. Endocrinology. 1998; 139: 1927-1935Crossref PubMed Google Scholar, 12Guan R. Zhang Y. Jiang J. Baumann C.A. Black R.A. Baumann G. Frank S.J. Endocrinology. 2001; 142: 1137-1147Crossref PubMed Scopus (41) Google Scholar, 13Zhang Y. Guan R. Jiang J. Kopchick J.J. Black R.A. Baumann G. Frank S.J. J. Biol. Chem. 2001; 276: 24565-24573Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar). We have previously shown in cell culture model systems that GHR proteolysis (receptor loss, remnant accumulation, and variable degrees of GHBP shedding) can be induced by several stimuli: 1) pharmacologic activation of protein kinase C by the phorbol ester, PMA; 2) treatment with platelet-derived growth factor (PDGF); or 3) treatment of serum-starved cells with serum (11Alele J. Jiang J. Goldsmith J.F. Yang X. Maheshwari H.G. Black R.A. Baumann G. Frank S.J. Endocrinology. 1998; 139: 1927-1935Crossref PubMed Google Scholar, 12Guan R. Zhang Y. Jiang J. Baumann C.A. Black R.A. Baumann G. Frank S.J. Endocrinology. 2001; 142: 1137-1147Crossref PubMed Scopus (41) Google Scholar, 13Zhang Y. Guan R. Jiang J. Kopchick J.J. Black R.A. Baumann G. Frank S.J. J. Biol. Chem. 2001; 276: 24565-24573Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar, 14Zhang Y. Jiang J. Black R.A. Baumann G. Frank S.J. Endocrinology. 2000; 141: 4342-4348Crossref PubMed Scopus (116) Google Scholar). In each case, the inducible proteolysis is blocked by a metalloprotease inhibitor, and genetic reconstitution studies suggest that tumor necrosis factor-α converting enzyme (TACE, also known as ADAM-17, Refs. 15Black R.A. Rauch C.T. Kozlosky C.J. Peschon J.J. Slack J.L. Wolfson M.F. Castner B.J. Stocking K.L. Reddy P. Srinivasan S. Nelson N. Boiani N. Schooley K.A. Gerhart M. Davis R. Fitzner J.N. Johnson R.S. Paxton R.J. March C.J. Cerretti D.P. Nature. 1997; 385: 729-733Crossref PubMed Scopus (2656) Google Scholar and 16Moss M.L. Jin S.-L.C. Milla M.E. Burkhart W. Carter H.L. Chen W.-J. Clay W.C. Didsbury J.R. Hassler D. Hoffman C.R. Kost T.A. Lambert M.H. Leesnitzer M.A. McCauley P. McGeehan G. Mitchell J. Moyer M. Pahel G. Rocque W. Overton L.K. Schoenen F. Seaton T., Su, J.-L. Warner J. Willard D. Becherer J.D. Nature. 1997; 385: 733-736Crossref PubMed Scopus (1459) Google Scholar) can catalyze the processing (14Zhang Y. Jiang J. Black R.A. Baumann G. Frank S.J. Endocrinology. 2000; 141: 4342-4348Crossref PubMed Scopus (116) Google Scholar). In cells expressing either murine or rabbit (rb) GHRs, receptor proteolysis is accompanied by a decrease in the ability of subsequent stimulation with GH to elicit JAK2 activation, suggesting that metalloprotease-mediated heterologous desensitization may be a mechanism that impacts cellular responsiveness to GH (12Guan R. Zhang Y. Jiang J. Baumann C.A. Black R.A. Baumann G. Frank S.J. Endocrinology. 2001; 142: 1137-1147Crossref PubMed Scopus (41) Google Scholar). Conversely, prior treatment with GH, but not with a GH antagonist, renders cells resistant to inducible GHR proteolysis (13Zhang Y. Guan R. Jiang J. Kopchick J.J. Black R.A. Baumann G. Frank S.J. J. Biol. Chem. 2001; 276: 24565-24573Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar). This suggests that GH-induced receptor dimerization or a GH-induced conformational change in the receptor's extracellular dimerization domain and/or stem region may impede access to the cleaving enzyme. In this study, we examined GHR extracellular domain determinants for metalloprotease-mediated proteolysis. Using adenoviral infection to accomplish abundant receptor expression, we identified a cleavage site in the rbGHR juxtamembrane region of the extracellular domain. We tested the importance of the identity of this site in allowing receptor proteolysis to occur by performing mutagenesis experiments. Finally, by comparing cleavage-sensitive versus cleavage-resistant GHR mutants, we tested the effect of inducible receptor proteolysis on GH-induced signaling. PMA and routine reagents were purchased from Sigma Chemical Co. unless otherwise noted. Restriction endonucleases were obtained from New England Biolabs (Beverly, MA). Recombinant hGH was kindly provided by Eli Lilly Co. (Indianapolis, IN). Immunex Compound 3 (IC3), supplied by Immunex Corporation, is identical to Compound 2 (17Mohler K.M. Sleath P.R. Fitzner J.N. Cerretti D.P. Alderson M. Kerwar S.S. Torrance D.S. Otten-Evans C. Greenstreet T. Weerawarna K. Dronheim S.R. Petersen M. Gerhart M. Kozlosky C.J. March C.J. Black R.A. Nature. 1994; 370: 218-220Crossref PubMed Scopus (570) Google Scholar), except that the napthylalanine side chain is replaced by a tert butyl group. Talon Metal Affinity Resin, used for His-tagged protein purification, was from Clontech. HEK-293 cells (a gift from Dr. C. Wu, University of Pittsburgh) were maintained in Dulbecco's modified Eagle's medium (low glucose) (Cellgro, Inc.) supplemented with 7% fetal bovine serum (Biofluids, Rockville, MD) and 50 μg/ml gentamicin sulfate, 100 units/ml penicillin, and 100 μg/ml streptomycin (all Biofluids). Transient transfection was achieved by introducing pCDNA 3.1-driven plasmids encoding GHR mutants (3 μg per transfection; see below for construction) with or without murine JAK2 (1 μg per transfection), as indicated, using LipofectAMINE Plus (Invitrogen) according to the manufacturer's instructions. Adenoviral infection of HEK-293 cells was accomplished using methods previously reported (18Lu C. Schwartzbauer G. Sperling M.A. Devaskar S.U. Thamotharan S. Robbins P.D. McTiernan C.F. Liu J.-L. Jiang J. Frank S.J. Menon R.K. J. Biol. Chem. 2001; 276: 22892-22900Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar). The rbGHR cDNA was a kind gift of Dr. W. Wood, Genentech, Inc. Construction of the cDNA encoding rbGHRdel 297–406 has been described (19Frank S.J. Gilliland G. Kraft A.S. Arnold C.S. Endocrinology. 1994; 135: 2228-2239Crossref PubMed Scopus (107) Google Scholar, 20Zhang Y. Jiang J. Kopchick J.J. Frank S.J. J. Biol. Chem. 1999; 274: 33072-33084Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). This mutant (referred to herein as “wild-type” or WT) has intact extracellular and transmembrane domains, but lacks residues 297–406 in the cytoplasmic domain (the full-length rbGHR has 620 residues). Thus, the Box 1 region in the proximal cytoplasmic domain is intact, as is the distal two-thirds of the cytoplasmic domain, which contains known GHR tyrosine phosphorylation sites, but the major internalization motif is absent. This GHR mutant retains the ability to respond to GH by allowing tyrosine phosphorylation of itself and JAK2 (see Fig. 7) and STAT5 (data not shown). Ligation of rbGHRdel 297–406cDNA into the pcDNA 3.1 (−) eukaryotic expression vector was accomplished using XbaI and KpnI restriction endonucleases. A C-terminally His6-tagged version of rbGHRdel 297–406 (rbGHRdel 297–406-His) was prepared by PCR (sequences of oligonucleotide primers used available upon request) and ligated into the pAdlox (as in 18) adenoviral expression shuttle vector using the XbaI and KpnI 5′- and 3′-restriction sites, respectively. For preparation of cDNA encoding rbGHR1–274-Myc-His, the rbGHR cDNA was used as a template to first amplify the residue 1–274 region (sequences of primers available upon request). This product was ligated into the pcDNA6/Myc-His vector (Invitrogen) using KpnI and EcoRV restriction endonucleases. This yielded a cDNA encoding the first 274 residues of rbGHR followed by a 14-residue spacer and the Myc and His tags on the C terminus (rbGHR1–274-Myc-His) in the pcDNA vector. This receptor mutant lacks most of the cytoplasmic domain, but the presence of the C-terminal Myc tag allows easy detection of the receptor and its remnant with anti-Myc antibodies. To transfer this receptor-encoding cDNA into the pAdEasy adenoviral expression system, the fragment was removed with KpnI andPmeI and ligated into the pAdTrack shuttle vector at theKpnI and EcoRV sites. cDNAs expression vectors encoding the rbGHR cleavage region mutants, rbGHR-Δ237–239, rbGHR-Δ240–242, rbGHR-Δ242–244, rbGHR-237–239AAA, rbGHR-240–242AAA, and rbGHR-242–244AAA, were each constructed using the ExSite (Stratagene) PCR-based site-directed mutagenesis method and the pCDNA3.1-rbGHRdel 297–406as the template. Sequences for the mutagenic oligonucleotides are available upon request. The deletion (Δ) mutations removed in-frame the three contiguous amino acids indicated (numbering as in Ref. 5Leung D.W. Spencer S.A. Cachianes G. Hammonds R.G. Collins C. Henzel W.J. Barnard R. Waters M.J. Wood W.I. Nature. 1987; 330: 537-543Crossref PubMed Scopus (1318) Google Scholar), while the alanine replacement mutations (AAA) changed the indicated residues to alanine. The entire protein coding sequence of each selected mutant cDNA was subjected to dideoxy DNA sequencing (UAB core facility), which verified the presence of the desired mutations and the absence of unwanted mutations. The methods for generating the adenovirally expressed version of rbGHRdel 297–406-His were as referred to in Ref. 18Lu C. Schwartzbauer G. Sperling M.A. Devaskar S.U. Thamotharan S. Robbins P.D. McTiernan C.F. Liu J.-L. Jiang J. Frank S.J. Menon R.K. J. Biol. Chem. 2001; 276: 22892-22900Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar. Briefly, linearized pAdlox-rbGHRdel 297–406-His and ψ5 helper virus DNA were cotransfected into CRE8 cells (21Hardy S. Kitamura M. Harris-Stansil T. Dai Y. Phipps M.L. J. Virol. 1997; 71: 1842-1849Crossref PubMed Google Scholar) (an HEK-293 derivative) by LipofectAMINE. The cells were harvested after several days when cytopathic effects became apparent. After lysis by three freeze/thaw cycles, cell debris was pelleted by centrifugation, and supernatant was collected. This supernatant was used for infection of HEK-293 cells. Three further rounds of infection were performed to obtain a high-titer viral stock, which was used for experimental and preparative infection. To generate adenovirally expressed rbGHR1–274-Myc-His, we used the Adeasy system (22He T.-C. Zhou S. da Costa L.T., Yu, J. Kinzler K.W. Vogelstein B. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 2509-2514Crossref PubMed Scopus (3221) Google Scholar). Briefly, pAdTrack-rbGHR1–274-Myc-His was linearized withPacI and was cotransformed with pAdeasy (helper plasmid) into electrocompetent Escherichia coli BJ5138 cells. Colonies harboring recombinants were selected by virtue of kanamycin resistance. Linearized recombinant plasmid was transfected into HEK-293 cells and high titer viral stock was obtained as above for the pAdlox system. The 9E10 anti-Myc monoclonal antibody and the 4G10 monoclonal antiphosphotyrosine (anti-pTyr) antibody were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY), as was the anti-p-JAK2 state-specific antibody reactive with JAK2 that is phosphorylated at residues Tyr1007 and Tyr1008(reflective of JAK2 activation). The rabbit polyclonal antisera, anti-GHRcyt-AL47, raised against a bacterially expressed N-terminally His-tagged fusion protein incorporating human GHR residues 271–620 (the entire cytoplasmic domain, Ref. 5Leung D.W. Spencer S.A. Cachianes G. Hammonds R.G. Collins C. Henzel W.J. Barnard R. Waters M.J. Wood W.I. Nature. 1987; 330: 537-543Crossref PubMed Scopus (1318) Google Scholar), has been previously described (13Zhang Y. Guan R. Jiang J. Kopchick J.J. Black R.A. Baumann G. Frank S.J. J. Biol. Chem. 2001; 276: 24565-24573Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar). Anti-GHRcyt-mAb is a mouse monoclonal antibody directed against a bacterially expressed GST fusion protein incorporating human GHR residues 271–620 and has been previously described (20Zhang Y. Jiang J. Kopchick J.J. Frank S.J. J. Biol. Chem. 1999; 274: 33072-33084Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). Anti-JAK2AL33 (directed at residues 746–1129 of murine JAK2) polyclonal serum has been described (23Jiang J. Liang L. Kim S.-O. Zhang Y. Mandler R. Frank S.J. Bioch. Biophys. Res. Comm. 1998; 253: 774-779Crossref PubMed Scopus (50) Google Scholar). Serum starvation of HEK-293 transfectants and infectants was accomplished by substitution of 0.5% (w/v) bovine serum albumin (fraction V, Roche Molecular Biochemicals, Indianapolis, IN) for serum in their respective culture media for 16–20 h prior to experiments. Unless otherwise noted, stimulations were performed at 37 °C. Details of the hGH (500 ng/ml) and PMA (at 1 μg/ml) treatment protocols have been described (11Alele J. Jiang J. Goldsmith J.F. Yang X. Maheshwari H.G. Black R.A. Baumann G. Frank S.J. Endocrinology. 1998; 139: 1927-1935Crossref PubMed Google Scholar, 12Guan R. Zhang Y. Jiang J. Baumann C.A. Black R.A. Baumann G. Frank S.J. Endocrinology. 2001; 142: 1137-1147Crossref PubMed Scopus (41) Google Scholar, 13Zhang Y. Guan R. Jiang J. Kopchick J.J. Black R.A. Baumann G. Frank S.J. J. Biol. Chem. 2001; 276: 24565-24573Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar, 14Zhang Y. Jiang J. Black R.A. Baumann G. Frank S.J. Endocrinology. 2000; 141: 4342-4348Crossref PubMed Scopus (116) Google Scholar, 20Zhang Y. Jiang J. Kopchick J.J. Frank S.J. J. Biol. Chem. 1999; 274: 33072-33084Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar, 24Goldsmith J.F. Lee S.J. Jiang J. Frank S.J. Am. J. Physiol. 1997; 273: E932-E941PubMed Google Scholar). Briefly, adherent cells (dish size and number as indicated in figure legends) were stimulated in binding buffer (BB, consisting of 25 mm Tris-HCl (pH 7.4), 120 mmNaCl, 5 mm KCl, 1.2 mm MgCl2, 0.1% (w/v) bovine serum albumin, and 1 mm dextrose) or Dulbecco's modified Eagle's medium (low glucose) with 0.5% (w/v) bovine serum albumin. Stimulations were terminated by washing the cells once with and then harvesting by scraping in ice-cold phosphate-buffered saline (PBS) in the presence of 0.4 mmsodium orthovanadate (PBS-vanadate). Pelleted cells were collected by brief centrifugation. For each cell type, pelleted cells were solubilized for 15 min at 4 °C in fusion lysis buffer (FLB) (1% (v/v) Triton X-100, 150 mm NaCl, 10% (v/v) glycerol, 50 mm Tris-HCl (pH 8.0), 100 mm NaF, 2 mm EDTA, 1 mm phenylmethylsulfonyl fluoride, 1 mm sodium orthovanadate, 10 mm benzamidine, 10 μg/ml aprotinin), as indicated. After centrifugation at 15,000 × g for 15 min at 4 °C, the detergent extracts were electrophoresed under reducing conditions or subjected to immunoprecipitations, as indicated. For immunoprecipitation of the GHR with the monoclonal anti-GHRcyt-MAb antibodies, 0.6 μg of purified antibody was used per precipitation. Protein-A Sepharose (Amersham Biosciences) was used to adsorb immune complexes. For deglycosylation of rbGHR mutants, immunoprecipitates were eluted and treatment with endoglycosidase H (Roche Molecular Biochemicals) or vehicle was carried out in accordance with previous published methods (25Silva C.M. Day R.N. Weber M.J. Thorner M.O. Endocrinol. 1993; 133: 2307-2313Crossref PubMed Scopus (41) Google Scholar, 26Yi W Kim S-O Jiang J Park S.H. Kraft A.S. Waxman D.J. Frank S.J. Mol. Endocrinol. 1996; 10: 1425-1443PubMed Google Scholar) and the manufacturer's suggestions. SDS sample buffer eluates were resolved by SDS-PAGE and immunoblotted as indicated. Resolution of proteins by SDS-PAGE, Western transfer of proteins, and blocking of Hybond-ECL (Amersham Biosciences) with 2% bovine serum albumin were performed as previously described (11Alele J. Jiang J. Goldsmith J.F. Yang X. Maheshwari H.G. Black R.A. Baumann G. Frank S.J. Endocrinology. 1998; 139: 1927-1935Crossref PubMed Google Scholar, 12Guan R. Zhang Y. Jiang J. Baumann C.A. Black R.A. Baumann G. Frank S.J. Endocrinology. 2001; 142: 1137-1147Crossref PubMed Scopus (41) Google Scholar, 13Zhang Y. Guan R. Jiang J. Kopchick J.J. Black R.A. Baumann G. Frank S.J. J. Biol. Chem. 2001; 276: 24565-24573Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar, 14Zhang Y. Jiang J. Black R.A. Baumann G. Frank S.J. Endocrinology. 2000; 141: 4342-4348Crossref PubMed Scopus (116) Google Scholar). Immunoblotting with antibodies 4G10 (1:4000), anti-GHRcyt-AL47 (1:1000), anti-Myc (1:2000), anti-pJAK2 (1:500), or anti-JAK2AL33(1:1000), with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (1:5000) and ECL detection reagents (all from Amersham Biosciences) and stripping and reprobing of blots were accomplished according to the manufacturer's suggestions. High titered adenovirus stock encoding rbGHR1–274-Myc-His, described above, was used to infect thirty 150 × 25 mm dishes of HEK-293 cells. After 24 h, the medium was removed, and serum-starvation was initiated. After 18 h, the cells were treated with PMA (1 μg/ml, final) for 30 min and then harvested and lysed with FLB, modified to lack EDTA. This detergent cell extract was applied to a TALON Metal Affinity Resin (Co2+-TC-Sepharose) column (15 ml). The column was washed twice with 50 ml of wash buffer (PBS with 0.5% (v/v) Triton X-100, and 1 mmphenylmethylsulfonyl fluoride), followed by three washes with 10 mm imidazole in PBS. Proteins bound to the column were eluted with 50 ml of PBS containing 150 mm imidazole. This eluate was concentrated by Centriprep-10K size exclusion. The concentrated sample was precipitated with ice-cold acetone. Proteins in this concentrate were resolved by SDS-PAGE (15% acrylamide) and electrically transferred to a polyvinylidene difluoride membrane (Millipore). A thin strip of the lane containing the purified proteins was cut off and immunoblotted with anti-Myc to verify the location of the band of interest. The remainder of the membrane was stained with Coomassie Brilliant Blue G250 and the Coomassie-stained band corresponding to the specific anti-Myc-identified remnant band was excised from the membrane for N-terminal sequencing by Edman degradation (27Matsudaira P. J. Biol. Chem. 1987; 262: 10035-10038Abstract Full Text PDF PubMed Google Scholar) using an AppliedBiosystems 494Ht sequencer. GHBP activity was measured in conditioned media by a standard GH binding assay, as previously reported (11Alele J. Jiang J. Goldsmith J.F. Yang X. Maheshwari H.G. Black R.A. Baumann G. Frank S.J. Endocrinology. 1998; 139: 1927-1935Crossref PubMed Google Scholar, 12Guan R. Zhang Y. Jiang J. Baumann C.A. Black R.A. Baumann G. Frank S.J. Endocrinology. 2001; 142: 1137-1147Crossref PubMed Scopus (41) Google Scholar, 28Baumann G. Shaw M.A. Amburn K. Metabolism. 1989; 38: 683-689Abstract Full Text PDF PubMed Scopus (140) Google Scholar). Conditioned medium (0.05 or 0.4 ml, as indicated) from cells treated as indicated was incubated with freshly labeled 125I-hGH (∼0.5 ng) for 45 min at 37 °C. Bound GH was then immediately separated from free GH by gel chromatography on a Sephadex G-100 column at 4 °C. The fraction of GH bound was determined by peak integration. Statistical analysis was performed by analysis of variance followed by Newman-Keuls test, or paired Student's t test as appropriate. Densitometric quantitation of ECL immunoblots was performed using a video camera and the Image 1.49 program (developed by W. S. Rasband, Research Services Branch, NIMH, Bethesda, MD). For normalization of GHBP shedding in the experiments in Fig. 5 B, the relative abundance of transfected GHRs among transfections within an each experiment was estimated by densitometric scanning of the mature GHR form present in the immunoblot (such as in Fig. 5 A). The measured GHBP shed into the supernatant of each sample was thus corrected by the abundance of receptor expressed within that transfection to facilitate comparison between wild-type and mutants. In the experiments shown in Fig. 8, the relative degree of basal and GH-induced specific JAK2 tyrosine phosphorylation in cell extracts from cells pretreated with PMA versusMe2SO vehicle was estimated by measuring the intensity of the pJAK2 signal, normalized for the abundance of JAK2 in the sample (by anti-JAK2AL33 immunoblot signal) for each condition. JAK2 activation induced by GH in the Me2SO-pretreated samples within each transfection was considered 100%. As indicated when graphically shown, pooled data from several experiments are displayed as the mean ± S.E. The significance of differences of pooled results is estimated by unpaired Student's t tests.Figure 8GHR proteolysis and heterologous desensitization of signaling. A, wild type. HEK-293 cells were transiently transfected with pcDNA 3.1-WT (rbGHRdel 297–406) plus pcDNA 3.1 JAK2 and divided into four equivalent samples. Serum-starved cells (one 90% confluent 60 × 15 mm dish per sample) were exposed to PMA (+) or the Me2SO vehicle (−) for 30 min prior to treatment with (+) or without (−) GH (500 ng/ml) for 10 min. Detergent cell extracts were resolved by SDS-PAGE and sequentially immunoblotted with anti-pJAK2 (upper panel) and anti-JAK2AL33 (lower panel). The positions of tyrosine-phosphorylated JAK2 and total JAK2 are indicated. Note the decreased GH-induced JAK2 activation in the sample pretreated with PMA. The data shown are representative of three such experiments.B, non-cleavable (rbGHR-Δ237–239) and cleavable (rbGHR-237–239AAA) mutants. HEK-293 cells were transiently transfected with pcDNA 3.1- rbGHR-Δ237–239 or pcDNA 3.1-rbGHR-237–239AAA plus pcDNA 3.1 JAK2 and each cotransfected pool was divided into four equivalent samples. Serum-starved cells (one 90% confluent 60 × 15-mm dish per sample) were exposed to GH with or without PMA pretreatment, as in A. Detergent cell extracts were resolved by SDS-PAGE in duplicate and immunoblotted with anti-pJAK2 (upper panel) and anti-JAK2AL33(lower panel). The positions of tyrosine-phosphorylated JAK2 and total JAK2 are indicated. In separate experiments (not shown), the specific 125I-hGH binding capacities of WT, rbGHR-Δ237–239, and rbGHR-237–239AAA transiently expressed in HEK-293 cells were quite similar (varying less than 10% between them). There was no significant 125I-hGH binding for HEK-293 cells transfected with the vector only. C, densitometric analysis of B. Multiple experiments for each receptor mutant shown in B (rbGHR-Δ237–239, n = 3; rbGHR-237–239AAA, n = 3) were analyzed densitometrically. Relative specific JAK2 tyrosine phosphorylation (mean ± S.E.), determined as under “Experimental Procedures,” is plotted. For each mutant, the level induced by GH in the absence of PMA pretreatment is considered 100%.View Large Image Figure ViewerDownload Hi-res image Download (PPT) To better characterize GHR structural determinants for proteolytic shedding and map the cleavage site, we sought to develop a transient expression system that would ensure high GHR levels, but maintain the characteristics of the system we previously defined. In prior work, we characterized a rbGHR mutant that has an in-frame deletion of residues 297–406 in the cytoplasmic domain. rbGHRdel 297–406, which lacks the internalization and UbE motif (29Allevato G. Billestrup N. Goujon L. Galsgaard E.D. Norstedt G. Postel-Vinay M.C. Kelly P.A. Nielsen J.H. J. Biol. Chem. 1995; 270: 17210-17214Abstract Full Text Full Text PDF PubMed Scopus (82) Google